BSE Live
Oct 14, 13:55Prev. Close
993.55
Open Price
992.75
Bid Price (Qty.)
980.00 (19)
Offer Price (Qty.)
980.65 (31)
NSE Live
Oct 14, 13:55Prev. Close
995.50
Open Price
995.00
Bid Price (Qty.)
980.05 (121)
Offer Price (Qty.)
980.40 (38)
Balance Sheet of Zydus Lifesciences (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
EQUITIES AND LIABILITIES | ||||||
SHAREHOLDER'S FUNDS | ||||||
Equity Share Capital | 102.40 | 102.40 | 102.40 | 102.40 | 102.40 | |
Total Share Capital | 102.40 | 102.40 | 102.40 | 102.40 | 102.40 | |
Reserves and Surplus | 4,423.00 | 3,527.50 | 2,809.10 | 2,446.90 | 1,987.50 | |
Total Reserves and Surplus | 4,423.00 | 3,527.50 | 2,809.10 | 2,446.90 | 1,987.50 | |
Total Shareholders Funds | 4,525.40 | 3,629.90 | 2,911.50 | 2,549.30 | 2,089.90 | |
NON-CURRENT LIABILITIES | ||||||
Long Term Borrowings | 583.60 | 853.60 | 794.10 | 684.40 | 474.40 | |
Deferred Tax Liabilities [Net] | 123.60 | 123.60 | 123.60 | 124.80 | 119.30 | |
Other Long Term Liabilities | 23.90 | 20.60 | 27.20 | 19.30 | 16.20 | |
Long Term Provisions | 80.50 | 46.80 | 32.80 | 47.60 | 35.10 | |
Total Non-Current Liabilities | 811.60 | 1,044.60 | 977.70 | 876.10 | 645.00 | |
CURRENT LIABILITIES | ||||||
Short Term Borrowings | 679.60 | 557.60 | 851.40 | 411.40 | 49.70 | |
Trade Payables | 671.30 | 461.70 | 360.70 | 284.80 | 345.90 | |
Other Current Liabilities | 330.00 | 298.60 | 269.50 | 410.30 | 180.50 | |
Short Term Provisions | 319.50 | 250.70 | 179.20 | 179.50 | 150.80 | |
Total Current Liabilities | 2,000.40 | 1,568.60 | 1,660.80 | 1,286.00 | 726.90 | |
Total Capital And Liabilities | 7,337.40 | 6,243.10 | 5,550.00 | 4,719.20 | 3,461.80 | |
ASSETS | ||||||
NON-CURRENT ASSETS | ||||||
Tangible Assets | 1,753.00 | 1,539.20 | 1,464.40 | 1,200.70 | 1,003.30 | |
Intangible Assets | 15.10 | 24.90 | 32.70 | 17.00 | 33.30 | |
Capital Work-In-Progress | 366.90 | 530.60 | 463.80 | 311.70 | 233.70 | |
Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Fixed Assets | 2,135.00 | 2,094.70 | 1,960.90 | 1,529.40 | 1,270.30 | |
Non-Current Investments | 1,750.80 | 1,265.30 | 1,064.00 | 1,102.50 | 566.50 | |
Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Long Term Loans And Advances | 754.30 | 803.20 | 716.70 | 565.80 | 332.00 | |
Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Non-Current Assets | 4,640.10 | 4,163.20 | 3,741.60 | 3,197.70 | 2,168.80 | |
CURRENT ASSETS | ||||||
Current Investments | 458.30 | 292.40 | 215.90 | 109.70 | 132.30 | |
Inventories | 804.30 | 663.50 | 587.20 | 501.20 | 464.50 | |
Trade Receivables | 1,056.10 | 722.00 | 683.00 | 581.20 | 475.10 | |
Cash And Cash Equivalents | 129.40 | 89.40 | 91.60 | 118.30 | 42.40 | |
Short Term Loans And Advances | 201.90 | 270.90 | 191.00 | 191.60 | 139.90 | |
OtherCurrentAssets | 47.30 | 41.70 | 39.70 | 19.50 | 38.80 | |
Total Current Assets | 2,697.30 | 2,079.90 | 1,808.40 | 1,521.50 | 1,293.00 | |
Total Assets | 7,337.40 | 6,243.10 | 5,550.00 | 4,719.20 | 3,461.80 | |
OTHER ADDITIONAL INFORMATION | ||||||
CONTINGENT LIABILITIES, COMMITMENTS | ||||||
Contingent Liabilities | 1,420.40 | 1,242.20 | 1,238.10 | 1,256.60 | 602.60 | |
CIF VALUE OF IMPORTS | ||||||
Raw Materials | 362.10 | 290.70 | 236.00 | 175.90 | 155.30 | |
Stores, Spares And Loose Tools | 73.40 | 53.50 | 42.30 | 91.20 | 48.90 | |
Trade/Other Goods | 73.40 | 53.50 | 42.30 | 91.20 | 48.90 | |
Capital Goods | 60.80 | 41.40 | 111.20 | 71.80 | 49.60 | |
EXPENDITURE IN FOREIGN EXCHANGE | ||||||
Expenditure In Foreign Currency | 270.20 | 265.40 | 254.70 | 151.80 | 107.30 | |
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
EARNINGS IN FOREIGN EXCHANGE | ||||||
FOB Value Of Goods | 2,808.00 | 2,003.80 | 1,544.20 | 1,356.90 | 1,211.10 | |
Other Earnings | 158.60 | 57.50 | 79.40 | 106.70 | 90.60 | |
BONUS DETAILS | ||||||
Bonus Equity Share Capital | 72.97 | 72.97 | 72.97 | 72.97 | 72.97 | |
NON-CURRENT INVESTMENTS | ||||||
Non-Current Investments Quoted Market Value | 2,929.00 | 1,445.70 | 1,241.80 | 1,058.80 | 1,654.60 | |
Non-Current Investments Unquoted Book Value | 1,663.30 | 1,189.40 | 1,006.80 | 1,050.10 | 514.10 | |
CURRENT INVESTMENTS | ||||||
Current Investments Quoted Market Value | 120.10 | 40.10 | 13.10 | -- | -- | |
Current Investments Unquoted Book Value | 338.30 | 252.40 | 203.00 | 109.70 | 132.30 |
07.10.2025
19.09.2025
16.09.2025
10.09.2025
Zydus Life Standalone June 2025 Net Sales at Rs 2,588.30 crore, down 37.78% Y-o-Y
10.09.2025
Zydus Life Standalone June 2025 Net Sales at Rs 2,588.30 crore, down 37.78% Y-o-Y
24.06.2025
Zydus Life Consolidated March 2025 Net Sales at Rs 6,527.90 crore, up 17.96% Y-o-Y
21.05.2025
Zydus Life Standalone March 2025 Net Sales at Rs 5,819.60 crore, up 74.64% Y-o-Y
05.02.2025
Zydus Life Standalone December 2024 Net Sales at Rs 2,515.90 crore, up 6.1% Y-o-Y
12.07.2023
Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang
08.07.2022
Zydus Lifesciences Q1 PAT may dip 10.6% YoY to Rs 505.2 cr: Prabhudas Lilladher
13.01.2022
Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher
06.10.2021
Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher